The prognostic role of systemic inflammatory markers in apparent early-stage ovarian cancer

Background Few studies analyzed the prognostic role of systemic inflammatory markers in early-stage ovarian cancer. The primary endpoint of the present study was to assess the prognostic impact of baseline inflammatory markers in early-stage ovarian cancer. The secondary endpoints were to compare the disease-free survival (DFS) of inflammatory markers with standard risk factors and to correlate these with BRCA mutational status. Methods Retrospective, single-center, observational study. Patients with FIGO-stage I-II and IIIA1 epithelial ovarian cancer undergoing primary surgery between 10/2012 and 12/2019 were included. Inflammatory markers were evaluated on the results of the complete blood count and coagulation tests, performed before ovarian cancer surgery. The Receiver Operating Characteristic curve was used to determine the optimal cut-off value of different baseline inflammatory biomarkers for the DFS analysis. Results Three hundred fifty-nine patients were included in the study period. Baseline neutrophil-lymphocyte ratio (NLR) >= 3 and systemic immune inflammation index (SII, defined as platelet x neutrophil-lymphocyte ratio) >= 1000 were associated with worse 3 year DFS and baseline SII >= 1000 was associated with worse 3 year OS. BRCA-mutated patients with SII >= 1000 and with NLR >= 3 had significantly worse DFS compared to SII < 1000 and with NLR < 3. FIGO stage > I was the only independent risk factor for higher risk of recurrence. Conclusion SII >= 1000 and NLR >= 3 were associated with worse 3 year DFS and SII >= 1000 was associated with worse 3 year OS. The subgroups of BRCA-mutated patients with higher inflammation markers (SII >= 1000 and NLR >= 3) were associated with worse DFS. These findings might be helpful to design personalized treatment and more intensive surveillance.